Pharming Group (Pharming Group) Common Stock

: $7.7 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Pharming Group's quarterly common stock increased from Jun. 2023 ($7.5 Mil) to Sep. 2023 ($7.7 Mil) and increased from Sep. 2023 ($7.7 Mil) to Dec. 2023 ($7.7 Mil).

Pharming Group's annual common stock increased from Dec. 2021 ($7.4 Mil) to Dec. 2022 ($7.5 Mil) and increased from Dec. 2022 ($7.5 Mil) to Dec. 2023 ($7.7 Mil).

Pharming Group Common Stock Historical Data

The historical data trend for Pharming Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

7.23

7.31

7.43

7.51

7.67

Pharming Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															7.51	7.52	7.54	7.65	7.67

Pharming Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharming Group (Pharming Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.